Dual PET/CT Imaging in Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

216 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare conventional PET/CT scan performed 1 hour after injection of the radioactive tracer FDG (PET/CT\[1\]) with PET/CT performed after 3 hours (PET/CT\[3\]) in a group of patients with biopsy verified lung cancer or high suspicion of lung cancer after initial work-up (chest x-ray and CT of thorax/upper abdomen), who are potentially operable.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice

NCT00675168

Lung Cancer

UNKNOWN PHASE4

FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer

NCT06877949

Metastatic Breast Cancer Response Monitoring

RECRUITING NA

FDG-PET/CT Imaging as Early Predictor of DP

NCT02476734

Lymphoma

COMPLETED

PET/MR Imaging in Lung Cancer

NCT03739281

Lung Cancer

TERMINATED NA

Choline PET/CT vs. Dual Time Point FDG PET/CT in Prostate Cancer

NCT02232724

Prostate Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators also want to:

* To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up (se Gold Standard 6.1.1)
* To compare SUVmax with the expression of GLUT1 and G-6-Pase in tumors
* To compare the expression of GLUT1 with the activity of G6Pase
* To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of relapse within a year after curative surgery

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lung cancer or high suspicion of lung cancer

After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer

Dual FDG-PET/CT

Intervention Type OTHER

Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dual FDG-PET/CT

Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cytologic/histologic-verified lung cancer or high suspicion of lung cancer after initial work up
* Candidate to curative intended surgery after initial work up (usually chest x-ray, CT of chest/upper abdomen and if needed spirometry).